Xeris Biopharma Holdings, Inc. XERS Product revenue, net — Product revenue, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s product revenue, net — product revenue, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s product revenue, net — product revenue, net?
- Xeris Biopharma Holdings, Inc. (XERS) reported product revenue, net — product revenue, net of $82.45M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s product revenue, net — product revenue, net changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s product revenue, net — product revenue, net increased by 42.6% year-over-year, from $57.8M to $82.45M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s product revenue, net — product revenue, net?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s product revenue, net — product revenue, net has grown at a 54.8% compound annual growth rate (CAGR), from $49.28M to $283M.
- What does product revenue, net — product revenue, net mean?
- This metric represents the total net sales generated from the sale of pharmaceutical products after accounting for returns, allowances, and rebates. It serves as a primary indicator of commercial success and market adoption for the company's therapeutic portfolio. Growth in this figure reflects the effective scaling of product distribution and patient access across the company's core therapeutic areas.